転移性淡明腎細胞癌に対する分子標的薬の効果と予後因子の検討

HANDLE Web Site オープンアクセス

書誌事項

タイトル別名
  • Prognostic Factors and Efficacy of Molecular Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma
  • テンイセイタンメイジンサイボウガン ニ タイスル ブンシ ヒョウテキヤク ノ コウカ ト ヨゴ インシ ノ ケントウ

この論文をさがす

抄録

We retrospectively reviewed the medical records of patients with metastatic clear cell renal cell carcinoma who received molecular targeted therapy between 2005 and 2011. Cancer-specific survival was analyzed using the Kaplan-Meier method. Predictors of cancer-specific survival were analyzed using the Cox regression hazards model. A total of 89 patients, consisting of 50 first line patients and 39 patients receiving prior cytokine were included in the analysis. The two-year cancer-specific survival rate of the firstlinegroup was 60.2% and that of theprior cytokinethe rapy group was 62.1%. In univariateanalysis, Karnofsky performance status (KPS) ＜80%, time from diagnosis to treatment less than one year, bone metastasis and C-reactive protein (CRP) ＞1.3 mg/dl in were statistically significant prognostic factors (p＜0.05). In multivariate analysis, time from diagnosis to treatment less than one year (HR 2.46, 95%CI 1.11-5.82, p＝0.025) and CRP (HR 4.92, 95%CI 2.23-11.3, p＜0.001) were independent prognostic factors. Time from diagnosis to treatment less than one year and CRP were independent prognostic factors in patients who received molecular targeted therapy.

収録刊行物

  • 泌尿器科紀要

    泌尿器科紀要 61 (4), 135-139, 2015-04

    泌尿器科紀要刊行会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ